Sangamo Therapeutics Inc (SGMO) News

Okay sounds like a plan.

Have a Great Weekend Y'all...🥳

SGMO...Adding here and bidding the open gap in the .50 range...🥳

INCORRECT...You need to read the filing...and what Code F means...The sales were mandatory for tax purposes...🥳

buy at support around 72-73

What the heck is going on this morning? Huge pre market volume and price has hit 0.95.

I believe the 50 million in near-term upfront license fees and milestone payments is already priced into the stock. I believe the real movement will come when Pfizer speaks about the Phase 3 dataset from the AFFINE trial in the up and coming months. Not to mention, we will probably see a press release about Pfizer discussing these data points with regulatory authorities in the November to December time frame.

"Pfizer reported that analyses of the full Phase 3 dataset from the AFFINE trial are ongoing and additional data will be presented at upcoming medical meetings. Giroctocogene fitelparvovec has been granted Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration (FDA), as well as Orphan Drug designations in the U.S. and the European Union. Pfizer reported that it will discuss these data with regulatory authorities in the coming months."

Needless to say, Im bullish on SGMO and i like the probability of a buy out. I will be placing my buy order tomorrow for 30,000 shares at .75

Good Luck to All!

NOW we're talkin' ...

August 6th news wasn’t bad but how long is the time horizon 2025ish ..Agreement leverages Sangamo’s proprietary capsid delivery platform and epigenetic regulation capabilities to address certain neurodegenerative diseases
Sangamo expected to receive $50 million in near-term upfront license fees and milestone payments and is eligible to earn up to $1.9 billion in development and commercial milestone payments across multiple medicines, as well as tiered royalties on net sales
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Sangamo has granted Genentech an exclusive license to Sangamo’s proprietary zinc finger repressors that are directed to the tau gene, which is critically involved in Alzheimer’s disease and other tauopathies, as well as an undisclosed second neurology target. Sangamo has also agreed to exclusively license to Genentech, for tau and the second neurology target, Sangamo’s proprietary, neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and brain transduction in nonhuman primates.

“Sangamo has been pioneering the field of genomic medicine for years to address devastating neurodegenerative diseases with limited current treatment options,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We strongly believe in the power of our zinc finger technology to regulate the expression of key genes involved in disease. The recent discovery of our industry-leading intravenously delivered AAV capsid, STAC-BBB, has the potential to address longstanding challenges in delivering therapeutics to the central nervous system. We are excited to share this powerful combination with Genentech to advance potential treatment options for devastating neurodegenerative disorders, and we are hopeful this could be the first of multiple capsid collaborations to come with other partners.”

“We are uniquely positioned with our collective experience, expertise and resources in neurological research to explore transformative approaches, including gene therapy, that treat neurodegenerative diseases,” said Boris L. Zaïtra, Head of Roche Corporate Business Development. “Through groundbreaking research and partnerships with companies such as Sangamo, we are committed to pursuing important breakthroughs in both early diagnosis and treatment. Our relentless pursuit of scientific innovation is taking us into areas of enormous unmet medical need and progress in treating diseases of the brain and nervous system.”

Under the terms of the agreement, Sangamo is responsible for completing a technology transfer and certain preclinical activities, and Genentech is responsible for all clinical development, regulatory interactions, manufacturing and global commercialization. Genentech is expected to pay Sangamo $50 million in near-term upfront license fees and milestone payments. Sangamo is eligible to earn up to $1.9 billion in development and commercial milestones spread across multiple potential products under the agreement and tiered royalties on net sales of such products, subject to certain specified reductions.

Sangamo continues to engage in business development discussions with additional potential collaboration partners about the Sangamo STAC-BBB capsid delivery platform, its epigenetic regulation capabilities, and other assets, including Fabry disease.

About Sangamo Therapeutics

Sangamo Therapeutics is a genomic medicine compa

The executives all dumped at .86 on August 26th filing millions of shares … interesting

SGMO...88...Closed above the 20ma...Looking for the $1 break again...🥳

Don't know....but I LIKE IT !!!


SGMO

OOH-LA-LA .. Breakout or head fake ???

SGMO...8069...Bouncing off the 50MA...🥳

TY...🥳

You too G ... And all SGMOers ... >> M

Have a Great Weekend...🥳

Burritoville

Get out your wallet , fellas ...

Have a Great 3 Day Weekend Y'all...🥳

C'mon 'lil fella ... 🏃🏃🏃

Your very welcome...🥳

Thanks much. Haven't had as much time for trading the last couple of weeks, so hadn't done a new chart.
Again, Thank You.

I am playing it the same way as last run ...will buy from .80s down .60 range or below if it gets there...50 crossed 200...now the 100 starting its cross of the 200...Chart setting up for the $1.48 break ...increasing the buys as it dips...🥳

That is going to be the Sweet Spot (40-50), if we can reach it before the next announcement.
Not knowing if it will get there for sure, Bidding starts by EOW for me.

PS: May be that part of the downward pressure for SGMO is, RCAT has been sliding down since last week. (Them being a big part of what is going on with SGMO.)
JMO

https://www.nasdaq.com/market-activity/stocks/rcat

SGMO...77s...Keep buying the dips...still bidding the open gap in the .40 range...🥳

But only because I know it won't stay there. Not at all the sinking feeling you get with a BS stock.
This is the settling of the PPS that I thought would happen, while we wait on the next bit of good news.
I'm calling it a good thing for those who are really paying attention to this stock.
GLTA
SGMO

If you liked it at .80, your going to like it even more at .70

Looks like they will take it lower today

SGMO...Added in the .82 range...🥳

That is exactly what I thought would happen when it dropped back to 80 that first time. And then a slow build back upward.
But not so far.

It's now a good amount of days gone by since this discussion,and the same situation is still the case, it would probably be better for a wash out high volume drop,then the slow bleeding and draining longs out day after day.

You hope, me too lol

Gap under .50 may fill soon...

I believe mid to low 70s is support.

I wouldn't mind that a bit. Especially since it's not going to stay there. 😜

Looks like we touch the 70s this week.

Breaking through support? May end up in that earlier gap after all?

Have a Great Weekend Y'all...🥳

Yes Indeed it does...🥳

Looking good georgie18 🥳

$SGMO

SGMO...9095...HOD...🥳

georgie18

Member Level
Re: None

Friday, August 23, 2024 7:50:53 AM

Post#
811
of 814
SGMO...856...Looking to scale in for another entry...Last move .30 range to $1.20 range...Owned SGMO...from .30 to .80 range...on the $1.20 move...Looking for $1.48 Breakout on next move...🥳

Agree!
on the $1.20 move...Looking for $1.48 Breakout on next move...
$SGMO

Except when it went from $1.50 to .30...lol...🥳

It has been very predictable so far

SGMO...856...Looking to scale in for another entry...Last move .30 range to $1.20 range...Owned SGMO...from .30 to .80 range...on the $1.20 move...Looking for $1.48 Breakout on next move...🥳

Higher high and higher low,reversal sign last 2 days,might be up up up time

Exactly. We can see where it's going, just needs that $ to land in the Revenue column.
And/or for another agreement to be announced.

When real $$$ starts getting reported by the company ... Look Out ...

I think it will definitely be there one day soon. (within the next 6 mths.)